| Literatürler Hematoloji Uzmanlık Derneği
Literatür Detay Bilgisi
The same site on LEDGF IBD domain represents therapeutic target for MLL leukemia and HIV.

Yazarlar : Murai MJ, Pollock J, He S et al

Yayın : Blood

Yayın Yılı : 2014

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/25305204

Konu : Lösemi

Literatür İçeriği :  

Abstract

Lens epithelium-derived growth factor (LEDGF) is a chromatin associated protein implicated in leukemia and HIV-1 infection. LEDGF associates with MLL fusion proteins and menin and is required for leukemic transformation. To better understand the molecular mechanism underlying the LEDGF IBD domain interaction with MLL fusion proteins in leukemia we determined the solution structure of the MLL-IBD complex. We found a novel MLL motif, IBM2 (Integrase Binding Motif 2), which binds to a well-defined site on IBD. Point mutations within IBM2 abolished leukemogenic transformation by MLL-AF9, validating that this newly identified motif is essential for the oncogenic activity of MLL fusion proteins. Interestingly, the IBM2 binding site on IBD overlaps with the binding site for the HIV integrase (IN) and IN was capable to efficiently sequester IBD from the menin-MLL complex. A short IBM2 peptide binds to the IBD domain directly and inhibits both the IBD-MLL/menin and IBD-IN interactions. Our findings show that the same site on IBD is involved in binding to MLL and HIV integrase, revealing an attractive approach to simultaneously target LEDGF in leukemia and HIV.

Copyright © 2014 American Society of Hematology.


Literatür Arşivi

Konusu Aynı Olan Diğer Materyaller
SunumlarVideolarOlgu Tartışması